A major advantage of DryPod™ is its patent-clean formulation
ACG, the most integrated global provider of solid-dosage and packaging solutions, has introduced DryPod™, an innovative cold-form laminate embedded with desiccant functionality to protect formulations that degrade rapidly when exposed to moisture.
The launch represents a meaningful advancement for pharmaceutical companies that have struggled with limited supply options, design rigidity, and functional constraints associated with existing desiccant cold-form films.
Robust moisture control is crucial for ensuring drug stability and potency across the entire retail shelf life. Yet, industry dependence on a single patented co-extrusion approach has resulted in machine compatibility barriers, compulsory use of certain lidding foils, lengthy procurement schedules, reduced supplier flexibility, and inconsistent technical support across manufacturing locations.
DryPod™ counters these challenges, enabling manufacturers to fortify product protection while retaining operational efficiency and regulatory alignment.
Departing from traditional co-extrusion, DryPod™ is developed using a proprietary lamination technique that guarantees stable performance across widely used blister-forming lines. This removes the necessity for specialised line modifications, allowing straightforward integration into existing equipment setups. The laminate’s compatibility with all PE-sealable lidding foils further reduces sourcing limitations and enhances supply-chain resilience globally.
DryPod’s™ patent-clean design provides a major competitive edge. Engineered to avoid conflicts with active patents in desiccant co-extrusion technology, it offers full legal assurance, supporting supplier diversification, manufacturing scale-up, and entry into new international markets.
Sign in to leave a comment.